MEDPAL AI is trading 5.26% up now at £4.00 after investors continued reacting to the August 4, 2026 July trading update, which reported record performance and annualised recurring revenue exceeding £8.6 million.
- The update highlighted 47,223 NHS prescription items, private prescription revenue above £180,000, and approximately £843,000 in SaaS annualised revenue.
- Fee shares began trading on August 7, 2026; the announcement did not explicitly link that admission to price movement.